Further analysis of UBE2C expression revealed that patients with low UBE2C expression exhibited better survival outcomes, particularly in melanoma patients receiving immune checkpoint blockade (ICB) therapy (Figure 5E,F), highlighting UBE2C as a potential risk gene. This evidence concerns the gene UBE2C and melanoma.